| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Jun'18 |
|---|---|---|---|---|---|---|
ASSETS | ||||||
Current assets | ||||||
Cash and cash equivalents | ||||||
65,292 | 72,256 | 97 | 696 | 820 | 8,604 | 0 |
Restricted cash | ||||||
149 | 154 | - | - | - | 89 | - |
Short-term deposits | ||||||
10,052 | 10,003 | - | - | - | 31,055 | - |
Related parties | ||||||
- | 50 | - | - | - | - | - |
Other current assets | ||||||
1,680 | 2,068 | - | - | - | 140 | - |
Prepaid expenses and other current assets | ||||||
- | - | 26 | 39 | 54 | - | - |
Total current assets | ||||||
77,173 | 84,531 | 123 | 736 | 875 | 39,888 | 0 |
Non-current assets | ||||||
Lease deposit | ||||||
5 | 5 | - | - | - | - | - |
Property and equipment, net | ||||||
2,039 | 1,881 | - | - | - | 887 | - |
In-process research and development ("R&D") | ||||||
4,177 | 4,556 | - | - | - | 4,556 | - |
Operating lease right-of-use asset | ||||||
1,066 | 1,148 | - | - | - | - | - |
Total non-current assets | ||||||
7,287 | 7,590 | - | - | - | 5,443 | - |
Deferred offering costs | ||||||
- | - | - | - | - | - | 64 |
Deferred tax asset | ||||||
- | - | - | 1 | - | - | - |
Marketable securities held in Trust Account | ||||||
- | - | 71,083 | 70,881 | 70,475 | - | - |
Total asset | ||||||
84,460 | 92,121 | 71,206 | 71,618 | 71,350 | 45,331 | 64 |
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
Current liabilities | ||||||
Trade account payables | ||||||
1,340 | 3,253 | - | - | - | 193 | - |
Other account payables | ||||||
2,380 | 2,596 | - | - | - | 1,396 | - |
Current portion of lease liabilities | ||||||
361 | 375 | - | - | - | - | - |
Related parties | ||||||
- | - | - | - | - | 50 | - |
Accounts payable and accrued expenses | ||||||
- | - | 738 | 234 | 61 | - | 1 |
Accrued offering costs | ||||||
- | - | - | - | 21 | - | - |
Income taxes payable | ||||||
- | - | 12 | 136 | 76 | - | - |
Promissory note - related party | ||||||
- | - | - | - | - | - | 40 |
Total current liabilities | ||||||
4,081 | 6,224 | 751 | 371 | 159 | 1,639 | 41 |
Non-current liabilities | ||||||
Lease liabilities - net of current portion | ||||||
740 | 856 | - | - | - | - | - |
Contingent liabilities | ||||||
641 | 585 | - | - | - | 889 | - |
Total non-current liabilities | ||||||
1,381 | 1,441 | - | - | - | 889 | - |
Deferred tax liability | ||||||
- | - | - | - | 0 | - | - |
Promissory note - related party | ||||||
- | - | - | 500 | 500 | - | - |
Total Liabilities | ||||||
- | - | 751 | 871 | 659 | - | 41 |
Common stock subject to possible redemption, 6,453,777 and 6,510,243 and no shares at redemption value as of September 30, 2019 and June 30, 2019, respectively | ||||||
- | - | 65,455 | 65,747 | 65,690 | - | - |
Shareholders' equity | ||||||
Common stock, $0.0001 par value ("Ordinary Shares"); Authorized -60,000,000 shares as of March 31, 2020 and December 31, 2019. Issued - 22,925,860 as of March 31, 2020 and December 31, 2019. Outstanding - 22,920,160 shares as of March 31, 2020 and 22,862,835 as of December 31, 2019. | ||||||
2 | 2 | 0 | 0 | 0 | - | 0 |
Preferred A shares (pre-merger - BiomX Ltd.) ("Preferred A Shares"); NIS 0.01 par value; Authorized 16,430,668 shares as of December 31, 2018. Issued and outstanding 7,543,831 shares as of December 31, 2018. | ||||||
- | - | - | - | - | 1 | - |
Preferred B shares (pre-merger - BiomX Ltd.) ("Preferred B Shares"); NIS 0.01 par value; Authorized 6,858,371 shares as of December 31, 2018. Issued and outstanding 5,170,357 shares as of December 31, 2018. | ||||||
- | - | - | - | - | 1 | - |
Additional paid in capital | ||||||
127,069 | 126,626 | 4,945 | 4,653 | 4,710 | 64,410 | 24 |
Accumulated deficit | ||||||
-48,073 | -42,172 | - | - | - | -21,609 | - |
Retained earnings | ||||||
- | - | 54 | 346 | 289 | - | -1 |
Total shareholders' equity | ||||||
78,998 | 84,456 | 5,000 | 5,000 | 5,000 | 42,803 | 23 |
Total liabilities and shareholders' equity | ||||||
84,460 | 92,121 | 71,206 | 71,618 | 71,350 | 45,331 | 64 |